Back to News
Market Impact: 0.15
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
Source: globenewswire.com
Healthcare & Biotech
Immunocore said it will present Phase 1 data on brenetafusp plus KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at a late-breaking oral session during the 2026 SITC meeting. The announcement provides no trial results or numerical efficacy or safety data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
IMCR0.40
More News
- Daiichi Sankyo’s first-half profit rises on cancer drug growth; shares up
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Linde delivers a good quarter and puts in a fix for an overhang on the stock
- Aspen Neuroscience prices IPO at $15 per share